Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bounameaux, H, Haas, S, Farjat, AE, Ageno, W, Weitz, JI, Goldhaber, SZ, Turpie, AGG, Goto, S, Angchaisuksiri, P, Nielsen, JD, Kayani, G, Schellong, S, Mantovani, LG, Prandoni, P & Kakkar, AK 2020, 'Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE', Thrombosis Research, vol. 191, pp. 103-112. https://doi.org/10.1016/j.thromres.2020.04.036

APA

Bounameaux, H., Haas, S., Farjat, A. E., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Schellong, S., Mantovani, L. G., Prandoni, P., & Kakkar, A. K. (2020). Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research, 191, 103-112. https://doi.org/10.1016/j.thromres.2020.04.036

CBE

Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Mantovani LG, Prandoni P, Kakkar AK. 2020. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research. 191:103-112. https://doi.org/10.1016/j.thromres.2020.04.036

MLA

Vancouver

Author

Bounameaux, Henri ; Haas, Sylvia ; Farjat, Alfredo E ; Ageno, Walter ; Weitz, Jeffrey I ; Goldhaber, Samuel Z ; Turpie, Alexander G G ; Goto, Shinya ; Angchaisuksiri, Pantep ; Nielsen, Joern Dalsgaard ; Kayani, Gloria ; Schellong, Sebastian ; Mantovani, Lorenzo G ; Prandoni, Paolo ; Kakkar, Ajay K. / Comparative effectiveness of oral anticoagulants in venous thromboembolism : GARFIELD-VTE. In: Thrombosis Research. 2020 ; Vol. 191. pp. 103-112.

Bibtex

@article{04d844a505514378a900daf732ffc674,
title = "Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE",
abstract = "INTRODUCTION: Randomized controlled trials have shown that direct oral anticoagulants (DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). However, there are limited post-marketing data describing the effectiveness and safety of the DOACs in the community setting. We aimed to compare the effectiveness of DOACs and VKAs on 12-month outcomes in a real-world VTE patient population.METHODS: The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE is an observational study designed to document real-world treatment practices. This intention-to-treat analysis included 7987 VTE patients initiated on either DOACs (N = 4791) or VKAs (N = 3196) with or without pre-treatment with parenteral anticoagulants. Treatment groups were balanced according to baseline characteristics, using overlapping propensity score weights.RESULTS: After adjustment for baseline characteristics, all-cause mortality was significantly lower with DOAC than with VKAs (hazard ratio [HR]: 0.73; 95% confidence interval [CI] 0.56-0.95. Patients receiving VKAs were more likely than those receiving DOACs to die of complications of VTE (4.7% vs 2.7%) or from bleeding (4.2% vs. 1.3%). There was no significant difference in recurrent VTE (HR: 0.91, 95% CI 0.71-1.18), major bleeding (HR 1.03, 95% CI 0.69-1.54), or overall bleeding (HR 0.96, 95% CI 0.81-1.14) with DOACs or VKAs.CONCLUSIONS: n this real-world analysis of VTE treatment, DOACs were associated with reduced all-cause mortality compared with VKAs, and similar rates of recurrent VTE and bleeding.",
author = "Henri Bounameaux and Sylvia Haas and Farjat, {Alfredo E} and Walter Ageno and Weitz, {Jeffrey I} and Goldhaber, {Samuel Z} and Turpie, {Alexander G G} and Shinya Goto and Pantep Angchaisuksiri and Nielsen, {Joern Dalsgaard} and Gloria Kayani and Sebastian Schellong and Mantovani, {Lorenzo G} and Paolo Prandoni and Kakkar, {Ajay K}",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = jul,
doi = "10.1016/j.thromres.2020.04.036",
language = "English",
volume = "191",
pages = "103--112",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Pergamon",

}

RIS

TY - JOUR

T1 - Comparative effectiveness of oral anticoagulants in venous thromboembolism

T2 - GARFIELD-VTE

AU - Bounameaux, Henri

AU - Haas, Sylvia

AU - Farjat, Alfredo E

AU - Ageno, Walter

AU - Weitz, Jeffrey I

AU - Goldhaber, Samuel Z

AU - Turpie, Alexander G G

AU - Goto, Shinya

AU - Angchaisuksiri, Pantep

AU - Nielsen, Joern Dalsgaard

AU - Kayani, Gloria

AU - Schellong, Sebastian

AU - Mantovani, Lorenzo G

AU - Prandoni, Paolo

AU - Kakkar, Ajay K

N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.

PY - 2020/7

Y1 - 2020/7

N2 - INTRODUCTION: Randomized controlled trials have shown that direct oral anticoagulants (DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). However, there are limited post-marketing data describing the effectiveness and safety of the DOACs in the community setting. We aimed to compare the effectiveness of DOACs and VKAs on 12-month outcomes in a real-world VTE patient population.METHODS: The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE is an observational study designed to document real-world treatment practices. This intention-to-treat analysis included 7987 VTE patients initiated on either DOACs (N = 4791) or VKAs (N = 3196) with or without pre-treatment with parenteral anticoagulants. Treatment groups were balanced according to baseline characteristics, using overlapping propensity score weights.RESULTS: After adjustment for baseline characteristics, all-cause mortality was significantly lower with DOAC than with VKAs (hazard ratio [HR]: 0.73; 95% confidence interval [CI] 0.56-0.95. Patients receiving VKAs were more likely than those receiving DOACs to die of complications of VTE (4.7% vs 2.7%) or from bleeding (4.2% vs. 1.3%). There was no significant difference in recurrent VTE (HR: 0.91, 95% CI 0.71-1.18), major bleeding (HR 1.03, 95% CI 0.69-1.54), or overall bleeding (HR 0.96, 95% CI 0.81-1.14) with DOACs or VKAs.CONCLUSIONS: n this real-world analysis of VTE treatment, DOACs were associated with reduced all-cause mortality compared with VKAs, and similar rates of recurrent VTE and bleeding.

AB - INTRODUCTION: Randomized controlled trials have shown that direct oral anticoagulants (DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). However, there are limited post-marketing data describing the effectiveness and safety of the DOACs in the community setting. We aimed to compare the effectiveness of DOACs and VKAs on 12-month outcomes in a real-world VTE patient population.METHODS: The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE is an observational study designed to document real-world treatment practices. This intention-to-treat analysis included 7987 VTE patients initiated on either DOACs (N = 4791) or VKAs (N = 3196) with or without pre-treatment with parenteral anticoagulants. Treatment groups were balanced according to baseline characteristics, using overlapping propensity score weights.RESULTS: After adjustment for baseline characteristics, all-cause mortality was significantly lower with DOAC than with VKAs (hazard ratio [HR]: 0.73; 95% confidence interval [CI] 0.56-0.95. Patients receiving VKAs were more likely than those receiving DOACs to die of complications of VTE (4.7% vs 2.7%) or from bleeding (4.2% vs. 1.3%). There was no significant difference in recurrent VTE (HR: 0.91, 95% CI 0.71-1.18), major bleeding (HR 1.03, 95% CI 0.69-1.54), or overall bleeding (HR 0.96, 95% CI 0.81-1.14) with DOACs or VKAs.CONCLUSIONS: n this real-world analysis of VTE treatment, DOACs were associated with reduced all-cause mortality compared with VKAs, and similar rates of recurrent VTE and bleeding.

U2 - 10.1016/j.thromres.2020.04.036

DO - 10.1016/j.thromres.2020.04.036

M3 - Journal article

C2 - 32422442

VL - 191

SP - 103

EP - 112

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -

ID: 61765857